The Patent Finder

Methods and Compositions for Decreasing Soluble Immune Receptor CD28

Biond Biologics Ltd.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,139,534Methods and Compositions for Decreasing Soluble Immune Receptor CD28
In force
 · High confidence
Biond Biologics Ltd.In forceHigh confidence
Application 18/735,940Methods and Compositions for Decreasing Soluble Immune Receptor CD28
Pending
Not granted
Biond Biologics Ltd.PendingNot granted
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Biond Biologics Ltd..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited